Insider Selling: LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO Sells 100,000 Shares of Stock

Key Points

• George W. Lemaitre, CEO of LeMaitre Vascular, sold 100,000 shares for $9,351,000 on August 6th, reducing his ownership to 1,727,003 shares, valued at approximately $161.49 million.
• LeMaitre Vascular reported $0.60 EPS for the latest quarter, exceeding estimates, and its revenue rose 15% year-over-year to $63.15 million.
• The company declared a quarterly $0.20 dividend, with an ex-dividend date of August 21st, representing a 0.9% yield and a payout ratio of 38.83%.

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) CEO George W. Lemaitre sold 100,000 shares of LeMaitre Vascular stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $93.51, for a total transaction of $9,351,000.00. Following the transaction, the chief executive officer directly owned 1,727,003 shares in the company, valued at approximately $161,492,050.53. This represents a 5.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

LeMaitre Vascular Stock Performance

NASDAQ LMAT traded down $1.98 on Friday, hitting $92.28. 149,596 shares of the stock traded hands, compared to its average volume of 189,703. The company has a debt-to-equity ratio of 0.46, a quick ratio of 13.83 and a current ratio of 13.96. The business's fifty day moving average is $83.15 and its two-hundred day moving average is $86.70. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $109.58. The firm has a market capitalization of $2.08 billion, a price-to-earnings ratio of 44.80, a PEG ratio of 2.32 and a beta of 0.79.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%. The company had revenue of $63.15 million during the quarter, compared to the consensus estimate of $62.48 million. During the same quarter in the prior year, the company earned $0.52 EPS. The firm's quarterly revenue was up 15.0% compared to the same quarter last year. As a group, equities analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 4th. Stockholders of record on Thursday, August 21st will be given a $0.20 dividend. The ex-dividend date of this dividend is Thursday, August 21st. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. LeMaitre Vascular's payout ratio is 38.83%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Cantor Fitzgerald lifted their price target on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a report on Wednesday. Barrington Research raised LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 target price for the company in a research report on Wednesday. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $98.00.

Institutional Trading of LeMaitre Vascular

Institutional investors have recently modified their holdings of the business. Parkside Financial Bank & Trust grew its stake in LeMaitre Vascular by 1,913.3% in the 2nd quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier's stock valued at $25,000 after buying an additional 287 shares in the last quarter. Opal Wealth Advisors LLC bought a new position in shares of LeMaitre Vascular in the first quarter worth $26,000. NBC Securities Inc. bought a new position in shares of LeMaitre Vascular in the first quarter worth $36,000. Geneos Wealth Management Inc. grew its position in shares of LeMaitre Vascular by 250.3% in the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock valued at $47,000 after purchasing an additional 398 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of LeMaitre Vascular during the 1st quarter valued at $50,000. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.